Therapeutic Asset Ratings

136 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Vepdegestrant HER2-negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CCC (48)
vv1 HER2-negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Tinengotinib HER2-negative Breast Cancer	TransThera Sciences (Nanjing), Inc.	P1/2	CCC (48)
Ganetespib HER2-negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CC (47)
mk-2206 HER2-negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CC (47)
Nelitolimod HER2-negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CC (46)
IMMUNOGLOBULIN G, ANTI-(HUMAN INSULIN-LIKE GROWTH FACTOR I RECEPTOR) (HUMAN MONOCLONAL HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL LIGHT CHAIN, DIMER HER2-negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CC (45)
Immunoglobulin G1, anti-(human neuregulin receptor HER3) (human monoclonal U3-1287 heavy chain), disulfide with human monoclonal U3-1287 ?-chain, dimer HER2-negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CC (44)
Onapristone HER2-negative Breast Cancer	University of Wisconsin, Madison	P2	CC (44)
Mirdametinib HER2-negative Breast Cancer	Memorial Sloan Kettering Cancer Center	P1/2	CC (42)
ADG 106 HER2-negative Breast Cancer	National University Hospital, Singapore	P1/2	CC (41)
Nuv-1511 HER2-negative Breast Cancer	Nuvation Bio Inc.	P1/2	CC (41)
Oxodotreotide HER2-negative Breast Cancer	RayzeBio, Inc.	P1/2	CC (41)
POLO-LIKE KINASE 1 INHIBITOR NMS-1286937 HER2-negative Breast Cancer	Antonio Giordano, MD	P1/2	CC (41)
Axitinib HER2-negative Breast Cancer	Lynkcell Europe	P1	CC (40)
Bgb-43395 HER2-negative Breast Cancer	BeOne Medicines	P1	CC (40)
BMS986310 HER2-negative Breast Cancer	Ono Pharmaceutical Co., Ltd.	P1	CC (40)
Rly-5836 HER2-negative Breast Cancer	Relay Therapeutics, Inc.	P1	CC (40)
Amcenestrant HER2-negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	C (39)
AQUOCOBALAMIN HER2-negative Breast Cancer	General Oncology, Inc.	P1	C (37)
Atirmociclib HER2-negative Breast Cancer	Olema Pharmaceuticals, Inc.	P1	C (37)
Axatilimab HER2-negative Breast Cancer	Dana-Farber Cancer Institute	P1	C (37)
Bgb-21447 HER2-negative Breast Cancer	BeOne Medicines	P1	C (37)
CARMUSTINE HER2-negative Breast Cancer	General Oncology, Inc.	P1	C (37)
CDX 1140 HER2-negative Breast Cancer	University of Texas Southwestern Medical Center	P1	C (37)

Showing 101 to 125 of 136 assets

PreviousPage 5 of 6Next